[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-stage-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-stage-lung-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100624645","prospective-phase-ii-clinical-study-of-stereotactic-body-proton-therapy-sbpt-for-lung-cancer-100624645",false,"NCT07412327","Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer","A Single-Center, Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Early-Stage Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. .Lung cancer confirmed by histology and\u002For cytology; and in the absence of pathological diagnosis, patients who meet the following conditions can also be included: diagnosed by more than 2 imaging modalities, and the clinical diagnosis of lung cancer is confirmed after multidisciplinary team (MDT) discussion.\n2. The clinical staging based on positron emission tomography(PET)-computer tomography(CT) examination is: cT1\\~3 N0M0, stage IA-IIB (AJCC eighth edition).\n3. Age: 18 years and above.\n4. Karnofsky(KPS) score ≥60.\n5. The doctor assesses that surgical treatment is not suitable or the patient refuses surgery.\n6. Relatively good organ function:\n7. Normal bone marrow function: white blood cell (WBC)≥3×109\u002FL, Platelet ≥80×109\u002FL, Hemoglobin(HGB)≥90g\u002FL\n8. Normal liver and kidney function:\n9. Total bilirubin, Aspartate Aminotransferase(AST), and ALT(Alanine Aminotransferase)≤2.0×upper limit of normal values;\n10. Creatinine clearance ≥60ml\u002Fmin or creatinine ≤1.5×upper limit of normal value\n11. The patient has signed an informed consent form and is willing and able to comply with planned study visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. Patients with other malignant tumors.\n2. Poorly controlled heart failure, respiratory failure, heart function, and lung function below grade 3 (including grade 3).\n3. Those whose laboratory test values do not meet relevant standards before enrollment.\n4. Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons.\n5. Women of childbearing age who have a positive pregnancy test and women who are breastfeeding.\n6. Patients considered inappropriate for inclusion by other investigators.","ALL","18 Years",{"count":19,"type":20},65,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study included patients with early-stage lung cancer cT1-3N0M0, stage IA-IIB (American Joint Committee on Cancer eighth edition staging, AJCC 8th ) who were inoperable or refused surgery. They were divided into peripheral type and central type according to the tumor location and received radical Stereotactic Body Proton Therapy (SBPT) for Early-Stage Non-Small Cell Lung Cancer. The prescribed dose for patients with peripheral lung cancer is 48-60Gray(Gy) (Relative Biological Effectiveness, RBE)\u002F4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)\u002F10-15 fractions. After treatment, follow-up visits will be conducted to observe short-term and long-term efficacy, adverse reactions and patient quality of life.",[26,27],"Early-Stage Lung Cancer","Lung Cancer",[29,30,31,26,32,33],"Proton therapy","hypofractionated radiotherapy","radiotherapy","lung cancer","SBPT","RECRUITING","2026-05-19",{"date":37,"type":38},"2026-05-22","ACTUAL",{"date":40,"type":38},"2026-02-24",{"date":42,"type":20},"2029-07-01",{"name":44,"class":45},"Guangzhou Concord Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100637941","application-of-electromagnetic-navigation-system-in-pulmonary-nodule-localization-100637941","NCT07595120","Application of Electromagnetic Navigation System in Pulmonary Nodule Localization","Electromagnetic Navigation-Guided Versus CT-Guided Localization of Pulmonary Nodules: A Multicenter, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. Solitary single nodule, scheduled for lung nodule puncture and localization;\n3. Chest CT (lung window mode) showing a maximum nodule diameter ≤ 2 cm;\n4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2;\n5. Voluntary participation, with signed informed consent.\n\nExclusion Criteria:\n\n1. Not suitable for video-assisted thoracoscopic surgery;\n2. The distance between the center of the lesion and the dome of the diaphragm is \\\u003C 3 cm;\n3. History of thoracic adhesion due to previous thoracotomy or pleural infection;\n4. Patients judged by the investigator to be unsuitable for preoperative transthoracic or transbronchial localization;\n5. Inability to complete follow-up or poor compliance.","80 Years",{"count":56,"type":20},400,[23],"This study aims to design and conduct a multicenter, prospective, randomized controlled post-market clinical trial to validate the clinical efficacy of high-precision electromagnetic navigation technology.",[60,26],"Pulmonary Nodules",[62,63,64,65],"ENB","CT-guided Percutaneous","pulmonary nodules","localization","NOT_YET_RECRUITING","2026-05-16",{"date":35,"type":38},{"date":70,"type":20},"2026-05",{"date":72,"type":20},"2027-04",{"name":74,"class":45},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100636351","septum-guided-segmentectomy-for-deep-early-stage-lung-cancer-sgs2512-100636351","NCT07564557","Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)","Effectiveness and Safety of Septum-guided Segmentectomy in Solid-dominant, Deep-seated Early-stage Non-small Cell Lung Cancer (≤2 cm): A Single-center, Prospective, Single-arm Clinical Trial","SGS2512","Inclusion Criteria:\n\n* Age 18-80 years\n* Clinical stage IA (cT1a-bN0M0)\n* tumor diameter ≤ 2 cm\n* Pathological feature: Solid-dominant lesion (CTR \\> 0.5)\n* Tumor location: Deep-seated within the lung parenchyma (inner 2\u002F3), defined as the tumor center being located in the inner 2\u002F3 region of the lung field on axial, coronal, and sagittal CT views\n* ECOG Performance Status: 0-1\n* Pulmonary function: FEV1 ≥ 60% predicted and DLCO SB ≥ 60% predicted\n* Participants must be willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Multiple pulmonary nodules or evidence of distant metastasis\n* Intraoperative confirmation of lymph node metastasis (N1\u002FN2) or pleural dissemination\n* History of previous ipsilateral lung surgery\n* History of other malignant tumors within the past 5 years\n* Presence of severe cardiovascular or cerebrovascular diseases that preclude surgical tolerance\n* Pregnancy or breastfeeding",{"count":84,"type":20},89,[23],"The purpose of this study is to evaluate the safety and effectiveness of a specialized surgical technique called \"Septum-guided Segmentectomy\" for treating early-stage lung cancer located deep within the lung tissue.Standard surgery for lung cancer often involves removing an entire lung lobe (lobectomy), which can significantly reduce a patient's breathing capacity. For small tumors, removing only a segment of the lung (segmentectomy) can preserve more healthy tissue. However, for tumors located deep in the lung, traditional segmentectomy is technically challenging and risks leaving cancer cells behind.In this study, surgeons will use the natural anatomical boundaries-the intersegmental veins and their surrounding thin membranes (septa)-as a guide to precisely remove the target lung segment. This \"septum-guided\" approach aims to ensure the cancer is completely removed while maximizing the preservation of healthy lung function.Participants will be followed for 3 years after surgery to monitor for cancer recurrence and assess their long-term recovery.",[88,89,90,91],"Non-small Cell Lung Cancer","Early-stage Lung Cancer","Deep-seated Lung Nodules","Solid-dominant Lung Cancer",[93,94,95,96,97,98,81],"Septum-guided Segmentectomy","Intersegmental Septum","VATS Segmentectomy","Precision Surgery","Lung-sparing Surgery","Anatomical Boundary","2026-04-26",{"date":101,"type":38},"2026-05-04",{"date":103,"type":38},"2026-04-01",{"date":105,"type":20},"2031-04-01",{"name":107,"class":45},"Shanghai Chest Hospital"]